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Objective: Surgical site infections and postoperative urinary tract infections are 
common causes of patient morbidity in urological surgery. Although the effective-
ness of perisurgical antimicrobial prophylaxis (AMP) in reducing surgical site infec-
tions and postoperative urinary tract infections is well established, there is a wide 
variation in the use of AMP.
Materials and Methods: Three panels of experts of the Taiwan Urological Association 
were invited to review the literature and the clinical path of each hospital, and to 
suggest recommendations for AMP in open and laparoscopic surgeries, office pro-
cedures, and endoscopic surgery in the urological field.
Results: First-generation cephalosporins, usually not recommended in American 
and European guidelines, were recommended as first-line prophylactic antibiotics in 
Taiwan. The duration of AMP for each urological procedure was recommended and 
was usually limited to the period of a high risk of bacterial invasion. In patients with 
high-risk factors that increase the susceptibility to infection, a more-advanced agent 
with a longer duration is recommended. We do not discuss this agent in this article, 
but that does not preclude its appropriate use, depending on specific situations, 
including medical intolerance, agent compatibility, a history of previous infection, 
and community resistance patterns.
Conclusions: Controlled trials employing well-designed protocols may clarify the 
efficacy and safety concerning the choice of AMP for urological procedures. Practical 
guidelines based on clinical studies can then hopefully be updated.
*Corresponding author. Buddhist Tzu Chi General Hospital, Taipei Branch, 289 Jianguo Road, 
Xindian City, Taipei 231, Taiwan.
E-mail: kevinchhsieh@yahoo.com
1.  Introduction
Surgical site infections (SSIs) and postoperative urinary 
tract infections (UTIs) are common causes of patient mor-
bidity with urological surgery. SSIs are a complication in 
up to 5% of clean extra-abdominal operations and up to 
20% of intra-abdominal procedures.1 SSIs almost double 
the costs of hospitalization, and patients with an SSI are 
more likely to require a prolonged stay in the hospital 
and suffer morbidity and mortality.2–5
Although the effectiveness of perisurgical antimicro-
bial prophylaxis (AMP) in reducing SSIs and postoperative 
UTIs is well established,6 there is a wide variation in use 
of periprocedural AMP, including the choice of agents, 
timing of administration, route of administration, and 
duration of prophylaxis.7
The use of AMP in urology has been controversial for 
many years, and it is still present in recent publications of 
European, Japanese and American guidelines.7–9 Most pre-
vious studies were poorly designed and lacked statistical 
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power. There were inconsistencies concerning definitions 
and assessment of risk factors. Several surveys among 
urologists have revealed wide differences in regimens 
and choice of antibiotics for prophylaxis.10–12
In an attempt to provide national guidance for prophy-
lactic antibiotics in surgery and reduce medical expendi-
tures and the emergence of resistant microorganisms in 
Taiwan, guidelines for AMP in surgery in Taiwan were is-
sued by the Infectious Diseases Society of the Republic 
of China and Taiwan Surgical Association in 2004.13 How-
ever, there are only three guidelines for AMP in urolo-
gical procedures, including transrectal prostate biopsy, 
transurethral prostate biopsy, and transurethral bladder 
tumor resection. These three published guidelines are 
out of date and difficult to follow. Therefore, we pro-
posed recommendations with the support of the Taiwan 
Urological Association (TUA) to optimize the use of pro-
phylactic antibiotics in urological procedures. Hopefully, 
this report will improve patient safety and reduce medical 
costs by standardizing AMP.
2.  Materials and Methods
Three panels of experts of the TUA were invited to review 
the literature and the clinical path of each hospital. The 
panel of experts from northern Taiwan dedicated to the 
issue on AMP for endourological surgeries, the panel of 
experts from central Taiwan for investigative urological 
procedures, and the panel of experts from southern Taiwan 
for open urological surgeries. Furthermore, the leaders of 
the three panel groups presented their tentative sugges-
tions in August 2008 at the annual meeting of the TUA. 
After updating the opinions from members of the TUA, the 
first draft of recommendations for AMP in urology was 
presented at the fifth biennial meeting of the Asian 
Association of UTIs and STDs, held in Taipei, Taiwan, in 
November 2008. We summarize below the consensus of 
the Committee of Genitourinary-infections and sexually-
transmitted diseases, of the TUA in July 2009.
2.1.  Characteristics of urological surgery
Several aspects of urological surgery differ from those of 
other surgeries. First, urine exposure in the surgical field is 
usually unavoidable. Intraprostatic bacteria are not easily 
detected, even though urine culture may show negative 
findings in patients with preoperative UTIs.14 Therefore, 
bacterial contamination is possible in surgical procedures 
of the prostate. An indwelling catheter is frequently used 
in urinary tract surgery, and the length of time a catheter is 
in place is longer than that with other surgeries.8 An intra-
corporeal stent, a type of foreign body, is sometimes used 
for diverse indications. Finally, high-pressure irrigation 
fluid is often needed to keep the visual field clear in many 
endourological surgeries. Because of these characteristics, 
the risks of SSIs or UTIs are higher in urological surgeries.
2.2.  Evaluating risk factors for SSIs
Risk factors were underestimated in most clinical trials. 
Patients with high-risk factors have increased susceptibil-
ity of infection, and more-advanced agents with longer 
duration treatment are recommended.15 Risk factors can 
be classified into general risk factors and urological risk 
factors. General risk factors include an advanced age, 
malnutrition such as hypoalbuminemia, diabetes, smoking, 
obesity, remote infections such as skin and pulmonary 
infections, an advanced cancer stage, an immunocom-
promised status, and a long preoperative hospital stay. 
Urological risk factors include surgery involving bowel 
segments, a neurogenic bladder, vesicoureteral reflux, uri-
nary obstruction, urinary stones, recurrent genitourinary 
infections, long-term urinary catheterization, and foreign 
bodies in the urinary tract such as a stent or prosthesis.7–9
2.3.  Good clinical practice in surgery
Besides AMP, good clinical practice in surgery is very impor-
tant in reducing perioperative infections.15 Preoperative 
issues include control of serum blood sugar, cessation of 
tobacco consumption, and washing and cleaning the body 
with an antiseptic agent. The preoperative hospital stay 
should be as short as possible, and the patient should 
not wear hand or arm jewelry. The hair should not be 
shaved preoperatively unless it interferes with the oper-
ation. If it has to be shaved, then the hair should be 
shaved immediately before the operation.
Intraoperative issues include good operating room 
ventilation; disinfection of the environment; regular micro-
biological sampling; and sterilization of instruments, sur-
gical attire, and drapes. Rapid flash sterilization is not 
recommended. Operation room ventilation should be 
maintained at positive-pressure with respect to adja-
cent areas.
Surgical techniques play an important role in prevent-
ing SSIs. Such techniques include handling tissues gently, 
maintaining effective hemostasis, maintaining vascular-
ity, avoiding hematomas, avoiding unnecessary injury, 
preventing hypothermia, removing devitalized tissues, 
eradicating dead and other unperfused spaces, avoiding 
foreign bodies, using drains and suture material appro-
priately, and minimizing the operative time. A drainage 
tube should be placed with a separate incision and with 
a closed suction system.
Strategies for postoperative care to prevent infection 
include washing the hands before changing a dressing, 
ensuring adequate incision wound care, providing proper 
fluid intake and nutrition, and properly educating the 
patient/family at discharge planning.15
2.4.  Principles of AMP
AMP and antibiotic therapy are different issues. AMP is 
only one of several measures to prevent infections and 
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can never compensate for proper hygiene and operative 
techniques. On the other hand, antibiotic therapy is for 
treatment of a clinically suspected or microbiologically 
proven infection.
The advantage of AMP is to minimize perioperative 
infectious complications and costs. The drawbacks of 
overuse of antibiotics include drug side effects, micro-
bial resistance, and increased medical expenditures.9 
In general, these guidelines follow regulations of the 
National Health Bureau, Taiwan.16 However, the European, 
American, and Japanese guidelines are applied whenever 
appropriate.7–9
Antimicrobials can be administered either parenter-
ally or orally. The parental dose should be given within 
30 minutes before an operation.7–9,15 Oral administra-
tion is as effective as the intravenous route, and it is rec-
ommended for some procedures when the patient can 
easily take the drug 1–2 hours before a procedure. 
An additional dose should be used every 3 hours during 
surgery. The duration of AMP in each procedure has not 
yet been adequately addressed; therefore, this issue is 
unresolved. In principle, the duration of AMP should be 
minimized.
First-generation cephalosporins are generally recom-
mended for operations not involving the gastrointestinal 
(GI) tract. Second-generation cephalosporins are recom-
mended for procedures involving the GI tract. Gentamicin, 
aztreonam, clindamycin, and vancomycin are suggested 
in cases of penicillin allergy.
The agent is not discussed in this article do not 
preclude their appropriate use, depending on specific 
situations that include medical intolerance, agent com-
patibility, a history of a previous infection, and commu-
nity resistance patterns.
2.5.  Classification of surgical wounds
Traditionally, surgical wounds are classified into four 
types: clean, clean-contaminated, contaminated, and 
dirty-infected wounds. Clean wounds refer to uninfected 
primarily closed surgical wounds that do not enter the 
urinary tract (e.g., simple nephrectomy or adrenalec-
tomy). Clean-contaminated wounds are those that enter 
the urinary tract under controlled conditions without 
the presence of infected tissues or bacteria (e.g., radical 
prostatectomy, pyeloplasty, or partial cystectomy). Con-
taminated wounds are surgeries involving untreated in-
fections, including UTIs, or procedures using the GI tract 
such as the ileal bladder.11 Dirty-infected wounds are 
those involving existing clinical infections during an op-
eration (e.g., removal of a perinephric abscess or repair 
of an open traumatized urinary tract.).8,9,15 However, the 
traditional classification of surgical procedures applies 
to open surgery but not to endourological interven-
tions.8,9 Because of the above-described characteristics 
of urological surgeries, the classification of transurethral 
surgery is still controversial.
3.  Results
The panels’ recommendations of a prophylactic regimen 
for each procedure are summarized as follows.
3.1.  Open and laparoscopic surgeries (Table 1)
3.1.1.  Clean-wound surgery
In clean-wound surgery, none or a single dose of first-
generation cephalosporins before the incision is recom-
mended. Postoperative AMP is not necessary for patients 
with no risk factors. For patients with risk factors, first-
generation cephalosporins or gentamicin for less than 1 day 
are recommended. For intrascrotal surgery, one dose of 
first-generation cephalosporins or gentamicin is recom-
mended for the high complication rate in scrotal surgery.17
3.1.2.  Clean-contaminated or large clean surgery
For clean-contaminated surgery such as a radical nephrec-
tomy, radical prostatectomy, pyeloplasty, cystectomy, or 
nephroureterectomy, first-generation cephalosporins and/
or gentamicin with a duration of 1–3 days are recom-
mended.18,19 We also recommend first-generation cepha-
losporins and/or gentamicin with a duration of 1–3 days in 
large clean wound operations8 because of massive tissue 
destruction and reactions and a possibly worse sequel 
of infection with operations such as open nephrectomy.
3.1.3.  Use of intestine in urologic surgery
Because the risk of infection in intestine-employed sur-
gery is high,20 we recommend first- or second-generation 
cephalosporins combined with aminoglycoside and/or 
metronidazole for a duration of 1–4 days in cases under-
going such a surgery, e.g., ileal conduit.
3.1.4.  Prosthesis implantation
For prosthesis implantation surgery, first- or second-
generation cephalosporins combined with aminoglyco-
side for a duration of 24 hours are suggested.21
3.1.5.  Laparoscopic surgery
The recommendation for AMP in laparoscopic surgery is 
the same as that for open surgery.22
3.2.  Investigative Procedures (Table 2)
3.2.1.  Cystoscopy, simple ureteroscopy, and 
urodynamic studies
For cystoscopy, simple ureteroscopy, and urodynamic stud-
ies, AMP is not necessary except in patients at risk. Risk fac-
tors of infection are a neurogenic bladder, transplant 
Y.H. Chou, et al
66 Vol. 22, 63–69, June 2011
Ta
bl
e 
1 
Re
co
m
m
en
da
tio
ns
 fo
r a
nt
im
ic
ro
bi
al
 p
ro
ph
yl
ax
is
 in
 o
pe
n 
an
d 
la
pa
ro
sc
op
ic
 u
ro
lo
gi
ca
l s
ur
ge
ry
Pr
oc
ed
ur
e 
Pr
op
hy
la
xi
s 
in
di
ca
te
d 
A
nt
im
ic
ro
bi
al
(s
) o
f c
ho
ic
e 
A
lte
rn
at
iv
e 
D
ur
at
io
n 
of
 
Re
m
ar
ks
 
 
 
an
tim
ic
ro
bi
al
(s
) 
th
er
ap
y 
(h
r)
Cl
ea
n-
w
ou
nd
 s
ur
ge
ry
 
N
on
e 
or
 a
 s
in
gl
e 
do
se
 o
f 
 
 
 
In
 p
at
ie
nt
s 
at
 ri
sk
,a
 1
st
 g
en
.
 
1s
t  g
en
. c
ep
ha
lo
sp
or
in
 
 
 
 
ce
ph
al
os
po
ri
n 
an
d/
or
 g
en
ta
m
ic
in
, ≤
 2
4 
hr
La
rg
e 
cl
ea
n 
su
rg
er
y 
A
ll 
1s
t  g
en
. c
ep
ha
lo
sp
or
in
 +
  
 
≤ 
72
Cl
ea
n-
co
nt
am
in
at
ed
 s
ur
ge
ry
 
 
ge
nt
am
ic
in
U
se
 o
f i
nt
es
tin
e 
in
 u
ro
lo
gi
c 
A
ll 
1s
t  o
r 2
nd
 g
en
. c
ep
ha
lo
sp
or
in
 +
  
 
≤ 
96
su
rg
er
y 
 
am
in
og
ly
co
si
de
 ±
 m
et
ro
ni
da
zo
le
Pr
os
th
es
is
 im
pl
an
ta
tio
n 
A
ll 
1s
t  o
r 2
nd
 g
en
. c
ep
ha
lo
sp
or
in
 +
  
 
≤ 
24
 
 
am
in
og
ly
co
si
de
La
pa
ro
sc
op
ic
 s
ur
ge
ry
 
 
 
 
 
A
s 
fo
r o
pe
n 
su
rg
er
y
a R
is
k 
fa
ct
or
s 
in
cl
ud
e 
bo
th
 g
en
er
al
 a
nd
 u
ro
lo
gi
ca
l r
is
k 
fa
ct
or
s.
 g
en
. =
 g
en
er
at
io
n.
Ta
bl
e 
2 
Re
co
m
m
en
da
tio
ns
 fo
r a
nt
im
ic
ro
bi
al
 p
ro
ph
yl
ax
is
 fo
r i
nv
es
tig
at
iv
e 
pr
oc
ed
ur
es
Pr
oc
ed
ur
e 
Pr
op
hy
la
xi
s 
A
nt
im
ic
ro
bi
al
(s
)  
A
lte
rn
at
iv
e 
D
ur
at
io
n 
of
 
Re
m
ar
ks
 
in
di
ca
te
d 
of
 c
ho
ic
e 
an
tim
ic
ro
bi
al
(s
) 
th
er
ap
y 
(h
r)
Cy
st
os
co
py
, u
re
te
ro
sc
op
y,
  
N
on
e 
 
 
 
In
 p
at
ie
nt
s 
at
 ri
sk
,a
 1
st
 g
en
. c
ep
ha
lo
sp
or
in
 a
nd
/o
r g
en
ta
m
ic
in
, 
si
m
pl
e 
ur
od
yn
am
ic
 s
tu
dy
 
 
 
 
 
≤ 
24
 h
r
Tr
an
sr
ec
ta
l p
ro
st
at
e 
bi
op
sy
 
A
ll 
Si
ng
le
 d
os
e 
flu
or
oq
ui
no
lo
ne
 
G
en
ta
m
ic
in
 1
 d
ay
 +
 1
st
 g
en
. 
 
 
 
ce
ph
al
os
po
ri
n 
or
al
ly
 fo
r 5
 d
 
 
 
Si
ng
le
 d
os
e 
ge
nt
am
ic
in
 +
 
 
 
flu
or
oq
ui
no
lo
ne
 o
ra
lly
 fo
r 3
 d
ES
W
L 
N
on
e 
 
 
 
In
 p
at
ie
nt
s 
at
 ri
sk
,a
 1
st
 g
en
. c
ep
ha
lo
sp
or
in
 ±
 g
en
ta
m
ic
in
, ≤
 2
4 
hr
a R
is
k 
fa
ct
or
s 
in
cl
ud
e 
bo
th
 g
en
er
al
 a
nd
 u
ro
lo
gi
ca
l r
is
k 
fa
ct
or
s.
 g
en
. =
 g
en
er
at
io
n;
 E
SW
L =
 e
xt
ra
co
rp
or
ea
l s
ho
ck
 w
av
e 
lit
ho
tr
ip
sy
.
Antimicrobial prophylaxis for urological surgery
Vol. 22, 63–69, June 2011 67
patients, immunocompromised patients, prosthetic joints, 
increased post-voiding residual urine, and vesicoureteral 
reflux.23–25
3.2.2.  Transrectal prostate biopsy
AMP is indicated in all patients undergoing a prostate biopsy, 
and several regimens are recommended: (1) single dose 
fluoroquinolones,26 e.g., levofloxacin; (2) two doses of gen-
tamicin at a 12-hour interval combined with first-generation 
cephalosporins orally for 5 days; and (3) a single dose of gen-
tamicin combined with fluoroquinolone orally for 3 
days.4–6,27 To date, there is no consensus on an enema to re-
duce the infection rate after a transrectal prostate biopsy.28,29
3.2.3.  Extracorporeal shock wave lithotripsy (ESWL)
The policy of antibiotic prophylaxis prior to SWL in patients 
with sterile pretreatment urine cultures is efficacious in 
reducing the rate of post-SWL UTIs. However, the strat-
egy of antibiotic prophylaxis is not cost-effective when 
taking into consideration mild post-SWL UTIs, if encoun-
tered, in most patients.30 For ESWL, AMP is not indicated 
in the absence of preoperative UTIs. AMP is recommended 
for patients at risk. High-risk factors include patients with 
known infectious stones, a past history of symptomatic 
UTIs or bacteremia after ESWL.
3.3.  Endoscopic surgery (Table 3)
3.3.1.  Percutaneous nephrolithotripsy
For percutaneous nephrolithotripsy, the recommended 
agent is first-generation cephalosporins given intrave-
nously combined with aminoglycoside for a duration of 
no longer than 3 days. For patients at risk, oral-form first-
generation cephalosporins for a further 3–7 days are sug-
gested. Alternative agents are second- or third-generation 
cephalosporins and fluoroquinolone.
3.3.2.  Ureteroscopic lithotripsy, transurethral 
resection of a bladder tumor, and 
cystolithotripsy
First-generation cephalosporins given intravenously for 
less than 24 hours are recommended. For patients at risk, 
oral-form first-generation cephalosporins for a further 
3 days are suggested. Alternative agents are aminogly-
coside and second-generation cephalosporins.31,32 AMP 
is still controversial for patients receiving ureteroscopic 
lithotripsy with or without insertion of a JJ catheter.
3.3.3.  Transurethral resection of the prostate and 
various types of laser prostatectomies
First-generation cephalosporins and/or gentamicin given 
parenterally for ≤ 72 hours are recommended. Oral-form T
ab
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first-generation cephalosporins for a further 3–7 days are 
also suggested. Alternative agents are aminoglycoside, 
second- or third-generation cephalosporins, and fluoro-
quinolone.33 This principle should also be applied to var-
ious types of laser prostatectomy.
4.  Discussion
AMP is widely employed in surgical procedures to prevent 
SSIs. However, its use is controversial in urological sur-
geries. Although a variety of prophylactic antibiotic regi-
mens have been suggested, those recommendations were 
often based on anecdotal evidence or on data collected 
unscientifically. In recent years, there have been many 
guidelines for AMP in urological surgery. Among them, 
there are inconsistencies concerning timing, the route 
of administration, the duration of the regimen, and the 
choice of antibiotics.
Choices of antimicrobial agents differ in American, 
European, and Japanese guidelines. Second- or third-
generation cephalosporins are antimicrobials of optimal 
choice for surgical prophylaxis whenever appropriate in 
urology as recommended by the European Association of 
Urology, compared with fluoroquinolones recommended 
by the American Urological Association. On the other 
hand, fluoroquinolones, penicillin/beta-lactamase inhibi-
tors, and first- or second-generation cephalosporin, which 
are used whenever appropriate on various occasions, 
are recommended as first-line options by the Japanese 
Urological Association. To date, there is no convincing evi-
dence in terms of efficacy, validity, risks of microbial re-
sistance, and medical economics to lend support to the 
superiority of one regimen over another or the primary 
choice of appropriate prophylactic agents.
First-generation cephalosporins, usually not recom-
mended in American and European guidelines, have long 
been recommended as first-line AMP for urological sur-
geries for many years in Taiwan. They appear to be ef-
fective for AMP in both general surgery and urology. We 
have not observed any serious side effects apart from the 
occasional allergic reaction as with all antibiotic medica-
tions. In addition, the significant relationship between mi-
crobial resistance and overuse of antibiotics justifies the 
use of first-generation cephalosporins for AMP. More 
research is required to verify the equal effectiveness be-
tween first-generation cephalosporins and fluoroquino-
lone or third-generation cephalosporins that are usually 
recommended in American and European guidelines.
Clearly, there is a need for evidence-based guide-
lines in each country. To date, there is little convincing 
scientific evidence accounting for the validity of these rec-
ommendations. In the future, controlled trials employing 
well-designed protocols may clarify the efficacy and safety 
concerning AMP for urological procedures. Practical guide-
lines based on clinical studies could then be updated. 
In conclusion, the advantages and disadvantages of AMP 
should be carefully weighed. Details of recommendations 
for AMP for each urological procedure are provided and 
should be carefully followed.
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Chieh-Shiang Wang, Shuo-Meng Wang, Ching-Hwa 
Yang, and Stephan S. Yang.
(2) Central panel
 Chin-Pao Chang, Wen-Chi Chen, Shang-Sen Lee, 
Jesun Lin, and Ta-Chong Lin.
(3) Southern panel
 Yii-Her Chou, Bang-Ping Jiann, Chih-Ming Lu, 
Chien-Tai Mei, Chien-Hui Ou, I-Jen Tseng, Chang-An 
Tu, and Chii-Jye Wang.
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